Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Foundayo Dosage Chart: 6 Strengths, 30-Day Steps, Prices
articleA table-first Foundayo (orforglipron) dosage chart for people already prescribed the pill: all six strengths with tablet descriptions, the at-least-30-days step rule from the July 2026 FDA label, missed-dose and restart rules, the medicines that cap or change the dose, what each dose did in the label trials, and self-pay prices per strength as of October 29, 2026.
Foundayo vs Wegovy Pill: Label, Dosing and Cost (2026)
comparisonThe two FDA-approved weight-loss tablets compared against their own FDA labels: Wegovy tablets (oral semaglutide) and Foundayo (orforglipron). How each is taken, dose steps, missed doses, who each label covers, what each label reports, drug interactions, switching and self-pay prices checked October 29, 2026, with the document behind each claim named and no winner declared.